Johnson & Johnson gene therapy update – What happens now?
The latest research news from Retina UK.
Search
Search results
Sirius clinical trial – Exon 13 mutation of USH2A
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.
Charities demand increase in benefits
Charities representing blind and partially sighted people are urging the UK Government to increase benefits in line with inflation rather than wages, when a decision is made at the end of the month.
Meet our volunteers: Martin Hills
Martin started volunteering for Retina UK in 2014 after retiring as a Chartered Civil Engineer.
Notice of the forthcoming Retina UK AGM – July 2025
Formal notice of the forthcoming Annual General Meeting in July 2025.
News: Notice of the forthcoming Retina UK AGM – September 2024
Formal notice of the forthcoming Annual General Meeting in September 2024.
Notice of the forthcoming Retina UK AGM – July 2022
This year the AGM will be held on Saturday, 9 July at 4.00pm:
Research update – ProQR
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Notice of the forthcoming Retina UK AGM – June 2023
Formal notice of the forthcoming Annual General Meeting in June 2023.
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.